Connor, Clark & Lunn Investment Management (CC&L)
TEVA icon

Connor, Clark & Lunn Investment Management (CC&L)’s Teva Pharmaceuticals TEVA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.53M Sell
192,766
-279,125
-59% -$9.3M 0.01% 646
2026
Q1 		$14.2M Buy
+471,891
New +$15.2M 0.03% 401
2025
Q4 		– Sell
-174,319
Closed -$3.52M – 1774
2025
Q3 		$3.52M Buy
+174,319
New +$3.06M 0.01% 683
2024
Q4 		– Sell
-823,544
Closed -$14.8M – 1634
2024
Q3 		$14.8M Buy
+823,544
New +$14.4M 0.07% 208
2023
Q2 		– Sell
-39,233
Closed -$347K – 1493
2023
Q1 		$347K Sell
39,233
-3,685
-9% -$36.4K ﹤0.01% 979
2022
Q4 		$391K Buy
+42,918
New +$374K ﹤0.01% 930
2021
Q2 		– Sell
-345,263
Closed -$3.98M – 1101
2021
Q1 		$3.98M Sell
345,263
-2,835,932
-89% -$32.5M 0.02% 408
2020
Q4 		$30.7M Sell
3,181,195
-182,881
-5% -$1.75M 0.18% 107
2020
Q3 		$30.3M Buy
3,364,076
+1,759,561
+110% +$18.6M 0.2% 102
2020
Q2 		$19.8M Buy
1,604,515
+1,087,898
+211% +$12.3M 0.14% 127
2020
Q1 		$4.64M Buy
+516,617
New +$5.29M 0.04% 265
2019
Q2 		– Sell
-838,120
Closed -$13.1M – 1068
2019
Q1 		$13.1M Sell
838,120
-1,373,412
-62% -$24.2M 0.09% 165
2018
Q4 		$34.1M Buy
2,211,532
+231,332
+12% +$4.74M 0.23% 82
2018
Q3 		$42.7M Buy
1,980,200
+72,875
+4% +$1.69M 0.24% 76
2018
Q2 		$46.4M Sell
1,907,325
-8,425
-0.4% -$172K 0.26% 69
2018
Q1 		$32.7M Buy
+1,915,750
New +$37.4M 0.2% 95

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TEVA Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Teva Pharmaceuticals (TEVA) stake by 59% in Q2 2026, selling an estimated $9.3M and leaving 192,766 shares worth $6.53M. The position accounts for 0.01% of the portfolio, ranked #646.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TEVA in Q1 2018 and has held it in 16 quarters since. The position peaked at $46.4M in Q2 2018. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 192,766 shares of Teva Pharmaceuticals worth $6.53M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 279,125 Teva Pharmaceuticals shares in Q2 2026, an estimated $9.3M.
  • Teva Pharmaceuticals made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #646 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Teva Pharmaceuticals in Q1 2018 and has held it in 16 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Teva Pharmaceuticals position peaked at $46.4M in Q2 2018.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.